Celgene Corporation
Celgene Corporation[edit | edit source]
Celgene Corporation was a global biopharmaceutical company that focused on the discovery, development, and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The company was headquartered in Summit, New Jersey, United States.
History[edit | edit source]
Celgene was founded in 1986 as a unit of the Celanese Corporation, a chemical company. It became an independent company in 1987. Over the years, Celgene grew through strategic acquisitions and the development of a robust pipeline of drugs.
In 2019, Celgene was acquired by Bristol-Myers Squibb in a deal valued at approximately $74 billion, one of the largest pharmaceutical mergers in history.
Products[edit | edit source]
Celgene's portfolio included several key products:
- Revlimid (lenalidomide): A drug used to treat multiple myeloma and myelodysplastic syndromes.
- Pomalyst (pomalidomide): Used for the treatment of multiple myeloma.
- Otezla (apremilast): A treatment for psoriatic arthritis and plaque psoriasis.
- Thalomid (thalidomide): Used for multiple myeloma and erythema nodosum leprosum.
Research and Development[edit | edit source]
Celgene was known for its strong focus on research and development, investing a significant portion of its revenue back into R&D. The company had a number of promising compounds in its pipeline, targeting various forms of cancer and inflammatory diseases.
Acquisitions[edit | edit source]
Celgene expanded its capabilities and product offerings through several strategic acquisitions, including:
- Abraxis BioScience: Acquired in 2010, bringing the drug Abraxane (paclitaxel protein-bound) into Celgene's portfolio.
- Receptos: Acquired in 2015, adding ozanimod, a drug for multiple sclerosis and ulcerative colitis, to its pipeline.
Corporate Social Responsibility[edit | edit source]
Celgene was committed to corporate social responsibility, focusing on improving patient access to medicines, supporting communities, and promoting environmental sustainability.
Acquisition by Bristol-Myers Squibb[edit | edit source]
In January 2019, Bristol-Myers Squibb announced its intention to acquire Celgene. The acquisition was completed in November 2019, creating a leading biopharmaceutical company with a strong portfolio of oncology, immunology, and cardiovascular products.
Legacy[edit | edit source]
Celgene's legacy continues through its contributions to the treatment of cancer and inflammatory diseases, as well as its impact on the biopharmaceutical industry through its innovative research and development efforts.
References[edit | edit source]
External Links[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD
